- Home
- KYMR vs PODD Comparison
KYMR vs PODD Comparison
Compare KYMR & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYMR | PODD |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 10.3B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | KYMR | PODD |
|---|---|---|
| Price | $119.36 | $148.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 26 | 21 |
| Target Price | $107.72 | ★ $341.48 |
| AVG Volume (30 Days) | 649.1K | ★ 2.0M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.67 |
| Revenue | $39,211,000.00 | ★ $2,708,100,000.00 |
| Revenue This Year | $10.61 | $24.55 |
| Revenue Next Year | $8.17 | $19.18 |
| P/E Ratio | ★ N/A | $55.68 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $40.10 | $126.40 |
| 52 Week High | $130.05 | $354.88 |
Technical Indicators
Market Signals| Indicator | KYMR | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 52.58 | 49.11 |
| Support Level | $108.87 | $145.59 |
| Resistance Level | $120.37 | $155.17 |
| Average True Range (ATR) | 4.70 | 5.20 |
| MACD | -0.55 | 0.69 |
| Stochastic Oscillator | 42.92 | 60.40 |
Price Performance
Historical ComparisonAbout KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.